The changes enacted under Section 174A represent a fundamental shift in the tax treatment of Research & Experimentation (R&E) expenditures, demanding a fresh approach from CPAs, tax professionals, and accounting firms. With the Section 41 R&D tax credit still in play, Section 174A now dictates the federal income tax treatment of domestic R&E expenditures, primarily affecting the timing of deductions or elective capitalization. This means documentation standards, consistency across filings, and coordination between Sections 41 and 174A have become materially more consequential.
The upcoming July 6, 2026, deadline for retroactive domestic R&E elections is critical, particularly for eligible small businesses. Many historical records were not developed with capitalization in mind, posing significant risks for missed deductions, unanticipated adjustments, or defensibility challenges if action is delayed.
This white paper provides a practical reference for CPAs navigating this evolving environment, offering key insights to support informed advisory decision-making. Learn how to guide your clients effectively before critical timing elections are made and opportunities permanently close.
In this white paper, you'll discover how to:
Understand the structural shift: Grasp the full implications of Section 174A for R&D advisory services and client planning.
Mitigate significant risks: Identify and address common financial and tax exposures, including underclaiming, poor documentation, and overlooking critical deadlines.
Optimize client benefits: Coordinate Section 41 credits with Section 174A deduction timing to maximize tax savings and cash flow.
Navigate compliance with confidence: Gain insights into heightened substantiation requirements, new Form 6765 reporting, and the interaction of R&D deductions with other tax calculations.
Download our white paper today to ensure your firm and your clients are prepared for these critical changes.
Complete the form to download your copy of "R&D Tax: Understanding Section 174A."
